article Open AccessTop 1% cited
Congestive heart failure in patients treated with doxorubicin
Cancer · 2003 · Vol. 97(11) · pp. 2869–2879
Sandra M. Swain✉(National Institutes of Health)Fredrick S. WhaleyMichael S. Ewer(The University of Texas MD Anderson Cancer Center)
Abstract
Doxorubicin-related CHF occurs with greater frequency and at a lower cumulative dose than previously reported. These findings further indicate that LVEF is not an accurate predictor of CHF in patients who receive doxorubicin.
Chemotherapy-induced cardiotoxicity and mitigationCancer Treatment and PharmacologyElectron Spin Resonance StudiesMedicineDoxorubicinCumulative doseCardiotoxicityHeart failureEjection fractionCumulative incidenceInternal medicineIncidence (geometry)Cardiology
MeSH terms
AdultAge FactorsAgedAged, 80 and overAntineoplastic AgentsDoxorubicinFemaleHeart FailureHumansMaleMiddle AgedRetrospective StudiesStroke VolumeVentricular Function, Left
Citations
2,244
FWCI
18.41
field-weighted impact
References
23
Percentile
99%
vs. same field & year
Citations per year
Cited by
Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention
Heart · 2017 · 518 citations
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
European Heart Journal · 2016 · 2,487 citations
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
Annals of Oncology · 2020 · 963 citations
Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategies
British Journal of Haematology · 2005 · 455 citations
Regulated cell death pathways in doxorubicin-induced cardiotoxicity
Cell Death and Disease · 2021 · 626 citations
References
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
Annals of Internal Medicine · 1979 · 2,419 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.